Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage

Infection and Immunity

Volumn 80, Issue 6, 2012, Pages 2186-2193

  Prevaes, Sabine M P J ^a,c   van Wamel, Willem J B ^b   de Vogel, Corné P ^b   Veenhoven, Reinier H ^c   van Gils, Elske J M ^a,c   van Belkum, Alex ^b,d   Sanders, Elisabeth A M ^a   Bogaert, Debby ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Research Center Linnaeus Institute   (Netherlands)

^d BIOMÉRIEUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; BVH3 PROTEIN; CBPA PROTEIN; CHIPS PROTEIN; CLFA PROTEIN; CLFB PROTEIN; EFB PROTEIN; ENO PROTEIN; HLGB PROTEIN; HYL PROTEIN; IGA 1 PROTEIN; IMMUNOGLOBULIN G; LUKD PROTEIN; LUKF PROTEIN; NANA PROTEIN; PDBD PROTEIN; PHT D PROTEIN; PILUS A PROTEIN; PLY PROTEIN; PNEUMOCOCCUS VACCINE; PPMA PROTEIN; PSAA PROTEIN; PSPA PROTEIN; SCIN PROTEIN; SIRA PROTEIN; SP0189 PROTEIN; SSL 3 PROTEIN; SSL 9 PROTEIN; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

AGE DISTRIBUTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; CROSS PROTECTION; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; AGING; ANTIBODY SPECIFICITY; BLOOD; HETEROZYGOTE; IMMUNOLOGY; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; STAPHYLOCOCCUS INFECTION;

AGING; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL PROTEINS; CARRIER STATE; CHILD, PRESCHOOL; HUMANS; IMMUNOGLOBULIN G; INFANT; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; VIRULENCE FACTORS;

EID: 85047688479     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00037-12     Document Type: Article

References (40)

1. Adrian PV, et al. 2004. Development of antibodies against pneumococcal proteins alpha-enolase, immunoglobulin A1 protease, streptococcal lipoprotein rotamase A, and putative proteinase maturation protein A in relation to pneumococcal carriage and otitis media. Vaccine 22:2737-2742.
2. Balaban N, Rasooly A. 2000. Staphylococcal enterotoxins. Int. J. Food Microbiol. 61:1-10.
3. Bogaert D, et al. 2006. Development of antibodies against the putative proteinase maturation protein A in relation to pneumococcal carriage and otitis media. FEMS Immunol. Med. Microbiol. 46:166 -168.
4. Bogaert D, et al. 2004. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 363:1871-1872.
5. Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R. 2009. Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect. Immun. 77:1613-1622.
6. de Haas CJ, et al. 2004. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199:687- 695.
7. Flasche S, et al. 2011. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a crosssectional study. PLoS Med. 8:e1001017.
8. Foster TJ. 2009. Colonization and infection of the human host by staphylococci: adhesion, survival and immune evasion. Vet. Dermatol. 20:456- 470.
9. Foster TJ, Hook M. 1998. Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. 6:484-488.
10. Foster TJ, McDevitt D. 1994. Surface-associated proteins of Staphylococcus aureus: their possible roles in virulence. FEMS Microbiol. Lett. 118: 199-205.
11. Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT. 2011. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect. Immun. 79:238 -245.
12. Hakenbeck R, Madhour A, Denapaite D, Bruckner R. 2009. Versatility of choline metabolism and choline-binding proteins in Streptococcus pneumoniae and commensal streptococci. FEMS Microbiol. Rev. 33:572- 586.
13. Harro C, et al. 2010. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans. Clin. Vaccine Immunol. 17:1868 -1874.
14. Jansen AG, et al. 2009. Invasive pneumococcal disease in the Netherlands: syndromes, outcome and potential vaccine benefits. Vaccine 27:2394- 2401.
15. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6:288 -301.
16. Ko YP, Liang X, Smith CW, Degen JL, Hook M. 2011. Binding of Efb from Staphylococcus aureus to fibrinogen blocks neutrophil adherence. J. Biol. Chem. 286:9865-9874.
17. Lebon A, et al. 2011. The inverse correlation between Staphylococcus aureus and Streptococcus pneumoniae colonization in infants is not explained by differences in serum antibody levels in the Generation R Study. Clin. Vaccine Immunol. 18:180 -183.
18. Lebon A, et al. 2011. Natural antibodies against several pneumococcal virulence proteins in children in the pre-pneumococcal vaccine-era: The Generation R Study. Infect. Immun. 79:1680 -1687.
19. Lowy FD. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111:1265-1273.
20. Lu YJ, et al. 2008. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4:e1000159.
21. Madhi SA, Schoub B, Simmank K, Blackburn N, Klugman KP. 2000. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1. J. Pediatr. 137:78-84.
22. McCarthy AJ, Lindsay JA. 2010. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol. 10:173.
23. Mitchell AM, Mitchell TJ. 2010. Streptococcus pneumoniae: virulence factors and variation. Clin. Microbiol. Infect. 16:411- 418.
24. Murphy E, et al. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum. Vaccin. 7(Suppl.):51-59.
25. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. 2007. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect. Immun. 75:350 -357.
26. Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. 2012. Novel proteinbased pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice. Infect. Immun. 80:461- 468.
27. Regev-Yochay G, et al. 2004. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA 292:716- 720.
28. Regev-Yochay G, Et Al. 2010. Re-Emergence Of The Type 1 Pilus Among Streptococcus Pneumoniae Isolates In Massachusetts, U. S. A. Vaccine 28:4842- 4846.
29. Roche FM, Meehan M, Foster TJ. 2003. The Staphylococcus aureus surface protein SasG and its homologues promote bacterial adherence to human desquamated nasal epithelial cells. Microbiology 149:2759 -2767.
30. Rodenburg GD, et al. 2011. Lower immunoglobulin G antibody responses to pneumococcal conjugate vaccination at the age of 2 years after previous nasopharyngeal carriage of Streptococcus pneumoniae. J. Pediatr. 159:965-970.
31. Rodenburg GD, et al. 2010. Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses. Vaccine 28:1391-1396.
32. Rodgers GL, Klugman KP. 2011. The future of pneumococcal disease prevention. Vaccine 29(Suppl. 3):C43-C48.
33. Shannon O, Uekotter A, Flock JI. 2006. The neutralizing effects of hyperimmune antibodies against extracellular fibrinogen-binding protein, Efb, from Staphylococcus aureus. Scand. J. Immunol. 63:184 - 190.
34. Shoma S, et al. 2011. Development of a multiplexed bead-based immunoassay for the simultaneous detection of antibodies to 17 pneumococcal proteins. Eur. J. Clin. Microbiol. Infect. Dis. 30:521-526.
35. van Gils EJ, et al. 2009. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302:159 - 167.
36. van Gils EJM, et al. 2011. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 6:e20229.
37. Verkaik NJ, et al. 2009. Anti-staphylococcal humoral immune response in persistent nasal carriers and noncarriers of Staphylococcus aureus. J. Infect. Dis. 199:625-632.
38. Verkaik NJ, et al. 2010. Induction of antibodies by Staphylococcus aureus nasal colonization in young children. Clin. Microbiol. Infect. 16:1312- 1317.
39. Verkaik NJ, van Wamel WJ, Avan B. 2011. Immunotherapeutic approaches against Staphylococcus aureus. Immunotherapy 3:1063- 1073.
40. Wertheim HF, et al. 2008. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med. 5:e17.